Valeant Takes Allergan Offer To Shareholders In Push To Get A Deal Done
This article was originally published in The Tan Sheet
Executive Summary
Valeant set out to control the story line around its drawn-out hostile bid for Allergan, which has raised questions about Valeant’s alternative business model, during a conference call June 17.